Apoptosis in pancreatic β-islet cells in Type 2 diabetes

Bosnian Journal of Basic Medical Sciences

Volumn 16, Issue 3, 2016, Pages 162-179

  Tomita, Tatsuo ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Amyloid; Apoptosis; Caspase; Hyperglycemia; Insulin; Islets of langerhans; Knockout mouse; Pro apoptotic genes; Type 2 diabetes; cells

Indexed keywords

APOPTOSIS REGULATORY PROTEIN;

ANIMAL; APOPTOSIS; GENETICS; HUMAN; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOLOGY;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MICE;

EID: 85013072367     PISSN: 15128601     EISSN: 18404812     Source Type: Journal    
DOI: 10.17305/BJBMS.2016.919     Document Type: Review

References (107)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phe-nomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26(4):239-57. http://dx.doi.org/10.1038/bjc.1972.33.
2. Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas: Estimation with a simple mathematical model. Diabetes 1995; 44(3):249-56. http://dx.doi.org/10.2337/diab.44.3.249.
3. Scaglia L, Cahill CJ, Finegood DT, Bonner-Weir S. Apoptosis partic-ipates in the remodeling of the endocrine pancreas in the neonatal rat. Endocrinology 1997; 138(4):1736-41. http://dx.doi.org/10.1210/endo.138.4.5069.
4. Mandrup-Poulsen T. beta-cell apoptosis: Stimuli and sig-naling. Diabetes 2001; 50 Suppl 1:S58-63. http://dx.doi.org/10.2337/diabetes.50.2007.S58.
5. Lee SC, Pervaiz S. Apoptosis in the pathophysiology of diabetes mellitus. Int J Biochem Cell Biol 2007; 39(3):497-504. http://dx.doi.org/10.1016/j.biocel.2006.09.007.
6. Emamaullee JA, Shapiro AM. Interventional strategies to pre-vent beta-cell apoptosis in islet transplantation. Diabetes 2006; 55(7):1907-14. http://dx.doi.org/10.2337/db05-1254.
7. Nakano M, Matsumoto I, Sawada T, Ansite J, Oberbroeckling J, Zhang HJ, et al. Caspase-3 inhibitor prevents apoptosis of human islets immediately after isolation and improves islet graft function. Pancreas 2004; 29(2):104-9. http://dx.doi.org/10.1097/00006676-200408000-00004.
8. Brandhorst D, Kumarasamy V, Maatoui A, Alt A, Bretzel RG, Brandhorst H. Porcine islet graft function is affected by pretreat-ment with a caspase-3 inhibitor. Cell Transplant 2006; 15(4):311-7. http://dx.doi.org/10.3727/000000006783981936.
9. Cheng G, Zhu L, Mahato RI. Caspase-3 gene silencing for inhibiting apoptosis in insulinoma cells and human islets. Mol Pharm 2008; 5(6):1093-102. http://dx.doi.org/10.1021/mp800093f.
10. Nicholson DW, Thornberry NA. Caspases: Killer proteases. Trends Biochem Sci 1997; 22(8):299-306. http://dx.doi.org/10.1016/S0968-0004(97)01085-2.
11. Chandra J, Zhivotovsky B, Zaitsev S, Juntti-Berggren L, Berggren PO, Orrenius S. Role of apoptosis in pancreatic beta-cell death in diabetes. Diabetes 2001; 50 Suppl 1:S44-7. http://dx.doi.org/10.2337/diabetes.50.2007.S44.
12. Peter ME, Krammer PH. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 1998; 10(5):545-51. http://dx.doi.org/10.1016/S0952-7915(98)80222-7.
13. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998; 391(6662):96-9. http://dx.doi.org/10.1038/34214.
14. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13(15):1899-911. http://dx.doi.org/10.1101/gad.13.15.1899.
15. Green DR. Apoptotic pathways: Ten minutes to dead. Cell 2005; 121(5):671-4. http://dx.doi.org/10.1016/j.cell.2005.05.019.
16. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C, et al. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: A potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 2001; 50(6):1290-301. http://dx.doi.org/10.2337/diabetes.50.6.1290.
17. Wajant H. The Fas signaling pathway: More than a paradigm. Science 2002; 296(5573):1635-6. http://dx.doi.org/10.1126/science.1071553.
18. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75(6):1169-78. http://dx.doi.org/10.1016/0092-8674(93)90326-L.
19. Allison J, Thomas HE, Catterall T, Kay TW, Strasser A. Transgenic expression of dominant-negative Fas-associated death domain protein in beta cells protects against Fas ligand-induced apopto-sis and reduces spontaneous diabetes in nonobese diabetic mice. J Immunol 2005; 175(1):293-301. http://dx.doi.org/10.4049/jimmunol.175.1.293.
20. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 2008; 29(3):303-16. http://dx.doi.org/10.1210/er.2007-0037.
21. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12):1595-607. http://dx.doi.org/10.2337/diab.37.12.1595.
22. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52(1):102-10. http://dx.doi.org/10.2337/diabetes.52.1.102.
23. Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol 2000; 24(3):297-302. http://dx.doi.org/10.1677/jme.0.0240297.
24. Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004; 89(11):5535-41. http://dx.doi.org/10.1210/jc.2004-0150.
25. Tomita T, Iwata K. Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Modern Pathol 1997; 10(1):47-54.
26. Perez SE, Cano DA, Dao-Pick T, Rougier JP, Werb Z, Hebrok M. Matrix metalloproteinases 2 and 9 are dispensable for pancreatic islet formation and function in vivo. Diabetes 2005; 54(3):694-701. http://dx.doi.org/10.2337/diabetes.54.3.694.
27. Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998; 187(4):587-600. http://dx.doi.org/10.1084/jem.187.4.587.
28. Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995; 81(5):801-9. http://dx.doi.org/10.1016/0092-8674(95)90541-3.
29. Gown AM, Willingham MC. Improved detection of apoptotic cells in archival paraffin sections: Immunohistochemistry using antibod-ies to cleaved caspase 3. J Histochem Cytochem 2002;50(4):449-54. http://dx.doi.org/10.1177/002215540205000401.
30. Martin SJ, Green DR. Protease activation during apoptosis: Death by a thousand cuts? Cell 1995; 82(3):349-52. http://dx.doi.org/10.1016/0092-8674(95)90422-0.
31. Tomita T. Immunocytochemical localisation of caspase-3 in pancreatic islets from type 2 diabetic subjects. Pathology 2010; 42(5):432-7. http://dx.doi.org/10.3109/00313025.2010.493863.
32. Bonner-Weir S. Life and death of the pancreatic beta cells. Trends Endocrinol Metab 2000; 11(9):375-8. http://dx.doi.org/10.1016/S1043-2760(00)00305-2.
33. Bonner-Weir S, O’Brien TD. Islets in type 2 diabetes: In honor of Dr. Robert C. Turner. Diabetes 2008; 57(11):2899-904. http://dx.doi.org/10.2337/db07-1842.
34. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005; 307(5708):380-4. http://dx.doi.org/10.1126/science.1104345.
35. Tomita T. Immunocytochemical localization of cleaved caspase-3 in pancreatic islets from type 1 diabetic subjects. Islets 2010; 2(1):24-9. http://dx.doi.org/10.4161/isl.2.1.10041.
36. Labat-Moleur F, Guillermet C, Lorimier P, Robert C, Lantuejoul S, Brambilla E, et al. TUNEL apoptotic cell detection in tissue sections: Critical evaluation and improvement. J Histochem Cytochem 1998; 46(3):327-34. http://dx.doi.org/10.1177/002215549804600306.
37. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcuta-neous xenografts. J Pathol 2003; 199(2):221-8. http://dx.doi.org/10.1002/path.1289.
38. Tomita T. Cleaved caspase-3 immunocytochemical staining for pancreatic islets and pancreatic endocrine tumors: A potential marker for biological malignancy. Islets 2010; 2(2):82-8. http://dx.doi.org/10.4161/isl.2.2.10807.
39. Ehrlich JC, Ratner IM. Amyloidosis of the islets of Langerhans. A restudy of islet hyalin in diabetic and non-diabetic individuals. Am J Pathol 1961; 38(1):49-59.
40. Höppener JW, Ahrén B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000; 343(9):411-9.
41. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amy-loid: A critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89(8):3629-43. http://dx.doi.org/10.1210/jc.2004-0405.
42. Butler AE, Janson J, Soeller WC, Butler PC. Increased beta-cell apop-tosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: Evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 2003; 52(9):2304-14. http://dx.doi.org/10.2337/diabetes.52.9.2304.
43. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 1987; 84(23):8628-32. http://dx.doi.org/10.1073/pnas.84.23.8628.
44. Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986; 140(3):827-31. http://dx.doi.org/10.1016/0006-291X(86)90708-4.
45. Kahn SE, Andrikopoulos S, Verchere CB. Islet amyloid: A long-rec-ognized but underappreciated pathological feature of type 2 diabe-tes. Diabetes 1999; 48(2):241-53. http://dx.doi.org/10.2337/diabetes.48.2.241.
46. Buse JB, Weyer C, Maggs DC. Amylin replacement with Pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome a barrier with insulin therapy. Clin Diabetes 2002; 20(3):137-44. http://dx.doi.org/10.2337/diaclin.20.3.137.
47. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglu-cagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002; 34(9):504-8. http://dx.doi.org/10.1055/s-2002-34790.
48. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ 1999; 25(3):389-97. http://dx.doi.org/10.1177/014572179902500310.
49. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Des 2001; 7(14):1353-73. http://dx.doi.org/10.2174/1381612013397357.
50. Tomita T. Islet amyloid polypeptide in pancreatic islets from type 2 diabetic subjects. Islets 2012; 4(3):223-32. http://dx.doi.org/10.4161/isl.20477.
51. Clark A, Nilsson MR. Islet amyloid: A complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia 2004; 47(2):157-69. http://dx.doi.org/10.1007/s00125-003-1304-4.
52. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988; 9(4):151-9.
53. Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, et al. ß-cell loss and ß-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 2011; 178(6):2632-40. http://dx.doi.org/10.1016/j.ajpath.2011.02.036.
54. Mirzabekov TA, Lin MC, Kagan BL. Pore formation by the cytotoxic islet amyloid peptide amylin. J Biol Chem 1996; 271(4):1988-92. http://dx.doi.org/10.1074/jbc.271.4.1988.
55. O’Brien TD, Glabe CG, Butler PC. Evidence for proteotoxic-ity in beta cells in type 2 diabetes: Toxic islet amyloid oligomers from intracellularly in the secretory pathway. Am J Pathol 2010; 176(2):861-9.
56. Anguiano M, Nowak RJ, Lansbury PT Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 2002; 41(38):11338-43. http://dx.doi.org/10.1021/bi020314u.
57. Engel MF, Khemtémourian L, Kleijer CC, Meeldijk HJ, Jacobs J, Verkleij AJ, et al. Membrane damage by human islet amyloid poly-peptide through fibril growth at the membrane. Proc Natl Acad Sci U S A 2008; 105(16):6033-8. http://dx.doi.org/10.1073/pnas.0708354105.
58. Jansen A, van Hagen M, Drexhage HA. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 1995; 345(8948):491-2. http://dx.doi.org/10.1016/S0140-6736(95)90586-3.
59. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300(5618):486-9. http://dx.doi.org/10.1126/science.1079469.
60. Ritzel RA, Butler PC. Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 2003; 52:1701-8. http://dx.doi.org/10.2337/diabetes.52.7.1701.
61. Tomita T. Amylin in human adult pancreatic islets. Pathology 2003; 35(1):34-6. http://dx.doi.org/10.1097/01268031-200335010-00005, http://dx.doi.org/10.1080/0031302021000062299.
62. Tomita T, Lacy PE, Matschinsky FM, McDaniel ML. Effect of alloxan on insulin secretion in isolated rat islets perifused in vitro. Diabetes 1974; 23(6):517-24. http://dx.doi.org/10.2337/diab.23.6.517.
63. Tomita T, Scarpelli DG. Interaction of cyclic AMP and alloxan on insulin secretion in isolated rat islets perifused in vitro. Endocrinology 1977; 100(5):1327-33. http://dx.doi.org/10.1210/endo-100-5-1327.
64. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: Many differences, few similarities. Diabetes 2005; 54 Suppl 2:S97-107. http://dx.doi.org/10.2337/diabetes.54.suppl_2.S97.
65. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005; 54 Suppl 2:S108-13. http://dx.doi.org/10.2337/diabetes.54.suppl_2.S108.
66. Bedoya FJ, Matschinsky FM, Shimizu T, O’Neil JJ, Appel MC. Differential regulation of glucokinase activity in pancreatic islets and liver of the rat. J Biol Chem 1986; 261(23):10760-4.
67. Matschinsky FM. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 1990; 39(6):647-52. http://dx.doi.org/10.2337/diab.39.6.647, http://dx.doi.org/10.2337/diabetes.39.6.647.
68. Matschinsky F, Liang Y, Kesavan P, Wang L, Froguel P, Velho G, et al. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest 1993; 92(5):2092-8. http://dx.doi.org/10.1172/JCI116809.
69. Shimizu T, Knowles BB, Matschinsky FM. Control of glucose phos-phorylation and glucose usage in clonal insulinoma cells. Diabetes 1988; 37(5):563-8. http://dx.doi.org/10.2337/diab.37.5.563.
70. MacDonald PE, Joseph JW, Rorsman P. Glucose-sensing mechanisms in pancreatic beta-cells. Philos Trans R Soc Lond B Biol Sci 2005; 360(1464):2211-25. http://dx.doi.org/10.1098/rstb.2005.1762.
71. De Vos A, Heimberg H, Quartier E, Huypens P, Bouwens L, Pipeleers D, et al. Human and rat beta cells differ in glucose trans-porter but not in glucokinase gene expression. J Clin Invest 1995; 96(5):2489-95. http://dx.doi.org/10.1172/JCI118308.
72. Iynedjian PB. Mammalian glucokinase and its gene. Biochem J 1993; 293:1-13. http://dx.doi.org/10.1042/bj2930001.
73. Newgard CB, McGarry JD. Metabolic coupling factors in pancreatic beta-cell signal transduction. Annu Rev Biochem 1995; 64:689-719. http://dx.doi.org/10.1146/annurev.bi.64.070195.003353.
74. Fridlyand L, Philson LH. Glucose sensing in the pancreatic beta cells: A computational systems analysis. Theor Biol Med Model 2010; 7(15):1-44. http://dx.doi.org/10.1186/1742-4682-7-15.
75. Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, et al. Close linkage of glucokinase locus on chromosome 7p to ear-ly-onset non-insulin-dependent diabetes mellitus. Nature 1992; 356(6365):162-4. http://dx.doi.org/10.1038/356162a0.
76. Porter JR, Barrett TG. Monogenic syndromes of abnormal glucose homeostasis: Clinical review and relevance to the understanding of the pathology of insulin resistance and beta cell failure. J Med Genet 2005; 42(12):893-902. http://dx.doi.org/10.1136/jmg.2005.030791.
77. Tattersall R. Maturity-onset diabetes of the young: A clinical history. Diabet Med 1998; 15(1):11-4. http://dx.doi.org/10.1002/(SICI)1096-9136(199801)15:1 <11:AID-DIA561>3.0.CO;2-0.
78. What is Maturity-Onset Diabetes of the Young (MODY)? National Diabetes Information Clearinghouse (NDIC) (National Institute of Diabetes and Digestive and Kidney Diseases) (NIH). [Last retrieved on 2008 Jul 29].
79. Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15(3):442-55. http://dx.doi.org/10.2337/diacare.15.3.442.
80. Kim WH, Lee JW, Suh YH, Hong SH, Choi JS, Lim JH, et al. Exposure to chronic high glucose induces beta-cell apoptosis through decreased interaction of glucokinase with mitochondria: Downregulation of glucokinase in pancreatic beta-cells. Diabetes 2005; 54(9):2602-11. http://dx.doi.org/10.2337/diabetes.54.9.2602.
81. Chan SL, Yu VC. Proteins of the bcl-2 family in apoptosis signalling: From mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol 2004; 31(3):119-28. http://dx.doi.org/10.1111/j.1440-1681.2004.03975.x.
82. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407(6805):770-6. http://dx.doi.org/10.1038/35037710.
83. Ou D, Wang X, Metzger DL, James RF, Pozzilli P, Plesner A, et al. Synergetic inhibition of tumor necrosis factor-related apoptosis-in-ducing ligand-induced apoptosis in human pancreatic beta cells by Bcl-2 and X-linked inhibitor of apoptosis. Hum Immunol 2005; 66(3):274-84. http://dx.doi.org/10.1016/j.humimm.2004.12.002.
84. Saldeen J. Cytokines induce both necrosis and apoptosis via a common Bcl-2-inhibitable pathway in rat insulin-producing cells. Endocrinology 2000; 141(6):2003-10. http://dx.doi.org/10.1210/endo.141.6.7523.
85. Boatright KM, Salvesen GS. Mechanisms of caspase activa-tion. Curr Opin Cell Biol 2003; 15(6):725-31. http://dx.doi.org/10.1016/j.ceb.2003.10.009.
86. Hui H, Dotta F, Di Mario U, Perfetti R. Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. J Cell Physiol 2004; 200(2):177-200. http://dx.doi.org/10.1002/jcp.20021.
87. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003; 424(6951):952-6. http://dx.doi.org/10.1038/nature01825.
88. Danial NN, Walensky LD, Zhang CY, Choi CS, Fisher JK, Molina AJ, et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat Med 2008; 14(2):144-53. http://dx.doi.org/10.1038/nm1717.
89. Antinozzi PA, Ishihara H, Newgard CB, Wollheim CB. Mitochondrial metabolism sets the maximal limit of fuel-stimu-lated insulin secretion in a model pancreatic beta cell: A survey of four fuel secretagogues. J Biol Chem 2002; 277(14):11746-55. http://dx.doi.org/10.1074/jbc.M108462200.
90. + and pancreatic B-cell function. Biochem Soc Trans 1994; 22(1):12-8. http://dx.doi.org/10.1042/bst0220012.
91. Liang Y, Bai N, Doliba C, Wang L, Barner DK, Matschinsky FM. Glucose metabolism and insulin release in mouse HC9 cells, as model of wild-type pancreatic beta cells. Am J Physiol 1996; 270:E846-57.
92. Luciani DS, White SA, Widenmaier SB, Saran VV, Taghizadeh F, Hu X, et al. Bcl-2 and Bcl-xL suppress glucose signaling in pancreatic ß-cells. Diabetes 2013; 62(1):170-82. http://dx.doi.org/10.2337/db11-1464.
93. Real PJ, Cao Y, Wang R, Nikolovska-Coleska Z, Sanz-Ortiz J, Wang S, et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 2004; 64(21):7947-53. http://dx.doi.org/10.1158/0008-5472.CAN-04-0945.
94. Yi CH, Pan H, Seebacher J, Jang IH, Hyberts SG, Heffron GJ, et al. Metabolic regulation of protein N-alpha-acetylation by Bcl-xL pro-motes cell survival. Cell 2011; 146(4):607-20. http://dx.doi.org/10.1016/j.cell.2011.06.050.
95. Rong YP, Bultynck G, Aromolaran AS, Zhong F, Parys JB, De Smedt H, et al. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc Natl Acad Sci U S A 2009; 106(34):14397-402. http://dx.doi.org/10.1073/pnas.0907555106.
96. Simonson DC. Hyperinsulinemia and its sequelae. Horm Metab Res Suppl 1990; 22:17-25.
97. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticu-lum stress in diabetes mellitus. Endocr Rev 2008; 29(1):42-61. http://dx.doi.org/10.1210/er.2007-0015.
98. Thomas HE, McKenzie MD, Angstetra E, Campbell PD, Kay TW. Beta cell apoptosis in diabetes. Apoptosis 2009; 14(12):1389-404. http://dx.doi.org/10.1007/s10495-009-0339-5.
99. Zhou YP, Pena JC, Roe MW, Mittal A, Levesetti M, Baldwin AC, et al. Overexpression of Bcl-xL in beta cells prevents cell death but impairs mitochondrial signal for insulin secretion. Am J Physiol Endocrinol Metab 2000; 278(2):E340-51.
100. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 dia-betes. Science 2005; 307(5708)384-7. http://dx.doi.org/10.1126/science.1104343.
101. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49(5):721-49.
102. Hundal RS, Inzucchi SE. Metformin: New understandings, new uses. Drugs 2003; 63(18):1879-94. http://dx.doi.org/10.2165/00003495-200363180-00001.
103. Gunton JE, Delhanty PJ, Takahashi SI, Baxter RC. Metformin rap-idly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2 and increase glucose uptake via increased GLUT-2 translocation. J Clin Endocrinol Metab 2003; 88(3):323-32. http://dx.doi.org/10.1210/jc.2002-021394.
104. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51 Suppl 3:S368-76. http://dx.doi.org/10.2337/diabetes.51.2007.S368.
105. Kendall DM. Thiazolidinediones: The case for early use. Diabetes Care 2006; 29(1):154-7. http://dx.doi.org/10.2337/diacare.29.01.06.dc05-0711.
106. Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36(11-12):867-76. http://dx.doi.org/10.1055/s-2004-826178.
107. Abdul-Ghani MA, Norton L, DeFrenzo RA. Role of sodium-glu-cose cotransporter 2 (SGLT-2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32(4):515-31. http://dx.doi.org/10.1210/er.2010-0029.